Corcept Therapeutics Incorporated (CORT)
Solvency ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.23 | 1.29 | 1.24 | 1.17 | 1.16 | 1.13 | 1.12 | 1.15 | 1.13 | 1.08 | 1.09 | 1.08 | 1.09 | 1.09 | 1.10 | 1.09 | 1.11 | 1.10 | 1.10 | 1.12 |
The solvency ratios of Corcept Therapeutics Inc, as depicted in the table, show that the company has maintained a consistently low level of indebtedness in relation to its assets, capital, and equity over the past eight quarters, with all ratios standing at 0.00. This indicates that the company is not heavily reliant on debt financing to support its operations and investments.
However, the financial leverage ratio has shown some fluctuation during the same period, ranging from 1.12 to 1.29. This ratio measures the extent to which the company relies on debt to finance its assets. The upward trend in the financial leverage ratio from Q1 2023 to Q3 2023 suggests a slight increase in the company's reliance on debt to fund its operations. It is important to monitor this ratio closely to ensure that the company's debt levels remain manageable and do not pose a risk to its financial stability.
Overall, Corcept Therapeutics Inc's solvency ratios indicate a conservative approach to debt management, as evidenced by the consistently low debt levels in relation to its assets, capital, and equity. However, the fluctuations in the financial leverage ratio highlight the importance of closely monitoring the company's debt levels to ensure long-term financial health and sustainability.
Coverage ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | — | — | — | — | 31.67 | 68.47 | 153.51 | 394.04 | 235.31 | 156.93 | 81.91 | 49.97 | 37.71 | 29.19 | 26.74 | 23.96 | 22.03 | 21.76 | 22.44 | 25.28 |
Based on the provided data, the interest coverage ratio for Corcept Therapeutics Inc is not available for the specified quarters in 2023 and 2022. The lack of information regarding the interest coverage ratio hinders the ability to assess the company's ability to cover its interest expenses with its earnings. It is crucial for investors and stakeholders to have this ratio to understand the company's financial health and its ability to meet its debt obligations. It is recommended that further analysis be conducted once the interest coverage data becomes available to gain insights into Corcept Therapeutics Inc's financial stability.